MANAGE
2018
Management of myocardial injury After NoncArdiac surGEry trial
In 1,754 patients with myocardial injury after non-cardiac surgery, dabigatran 110 mg twice daily reduced major vascular complications without a significant increase in major bleeding compared with placebo.
Result
Efficacy: Composite of vascular mortality, non-fatal MI, non-haemorrhagic stroke, arterial thrombosis, amputation and symptomatic venous thromboembolismHR 0.72 (95% CI 0.55-0.93) · P = 0.0115
Safety: Life-threatening, major or critical-organ bleedingHR 0.92 · P = 0.76
Below 1 favours dabigatran 110 mg twice daily, above 1 favours placebo.
Event rates Dabigatran 110 mg twice daily 11% vs placebo 15% (composite of vascular mortality, non-fatal MI, non-haemorrhagic stroke, arterial thrombosis, amputation and symptomatic venous thromboembolism)
- Subtopic
- Antithrombotic therapy
- Design
- Partial 2×2 factorial, double-blind, placebo-controlled RCT
- Relevance
- Important: one of several pillars.
- Source
- Devereaux PJ, Duceppe E, Guyatt G, et al. Lancet. 2018;391(10137):2325-2334.doi 10.1016/S0140-6736(18)30832-8
Discussion & critique
Stopped early for lack of funding, with study drug permanently discontinued in about 45 % of patients in both arms, so the estimate is diluted and the modest p value rests on a truncated design. It remains the only randomised evidence of any therapeutic strategy for myocardial injury after non-cardiac surgery.